Glatiramer acetate for the treatment of multiple sclerosis

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 4, 2004, Pages 875-891

  Wolinsky, Jerry S ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Copaxone; Glatiramere acetate; Immunomodulatory therapy; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

ALANINE; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CD4 ANTIGEN; CD69 ANTIGEN; COPOLYMER; GADOLINIUM; GLATIRAMER; GLUTAMIC ACID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOXANTRONE; MONOCLONAL ANTIBODY; MYELIN BASIC PROTEIN; NEUROTROPHIC FACTOR; NITRIC OXIDE; PLACEBO; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG;

ANXIETY DISORDER; ASTHENIA; BACKACHE; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DEPRESSION; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FEVER; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; MULTIPLE SCLEROSIS; NAUSEA; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PAIN; PARESTHESIA; PATHOGENESIS; PREGNANCY COMPLICATION; PRURITUS; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SKIN INFLAMMATION; SKIN NECROSIS; SYMPTOMATOLOGY; TACHYCARDIA; URINARY TRACT INFECTION; VASODILATATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; CONTROLLED CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES;

EID: 1842843695     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.4.875     Document Type: Review

References (87)

1. DHIB-JALBUT S: Glatiramer acetate (Copaxone®) therapy for multiple sclerosis. Pharmacol. Ther. (2003) 98:245-255.
2. LUBLIN FD, BAIER M, CUTTER G: Effect of relapses on development of residual deficit in multiple sclerosis. Neurology (2003) 61:1528-1532.
3. BJARTMAR C, FOX RJ: Pathological mechanisms and disease progression of multiple sclerosis: Therapeutic implications. Drugs Today (2002) 38:17-29.
4. COMI G: Why treat early multiple sclerosis patients? Curr. Opin. Neurol. (2000) 13:235-240 (Editorial).
5. GOODIN DS, ARNASON BG, COYLE PK, FROHMAN EM, PATY DW: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 61:1332-1338.
6. SELA M, TEITELBAUM D: Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin. Pharmacother. (2001) 2:1149-1165.
7. TEITELBAUM D, MESHORER A, HIRSHFELD T et al.: Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. (1971) 1:242-248.
8. LISAK RP, ZWEIMAN B, BLANCHARD N, BORKE LB: Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J. Neurol. Sci. (1983) 62:281-293.
9. KEITH AB, ARNON R, TEITELBAUM D, CASPARY EA, WISNIEWSKI HM: The effect of Cop-1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J. Neurol. Sci. (1979) 42:267-274.
10. FRIDKIS-HARELI M, NEVEU JM, ROBINSON RA et al.: Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J. Immunol. (1999) 162:4697-4704.
11. SMITH KJ, PYRDOL J, GAUTHIER L, WILEY DC, WUCHERPFENNIG KW: Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. (1998) 188:1511-1520.
12. AHARONI R, TEITELBAUM D, ARNON R, SELA M: Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. USA (1999) 96:634-639.
13. ARNON R, SELA M, TEITELBAUM D: New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J. Neurol. (1996) 243(Suppl. 1):S8-S13.
14. NEUHAUS O, FARINA C, WEKERLE H, HOHLFELD R: Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology (2001) 56:702-708.
15. CHEN M, GRAN B, COSTELLO K, JOHNSON K, MARTIN R, DHIB-JALBUT S: Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult. Scler. (2001) 7:209-219.
16. MILLER A, SHAPIRO S, GERSHTEIN S et al.: Treatment of multiple sclerosis with copolymer-1 (Copaxone): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. (1998) 92:113-21.
17. DUDA PW, SCHMIED MC, COOK SL, KREIGER JL, HAFLER DA: Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. (2000) 105:967-976.
18. DHIB-JALBUT S, CHEN M, SAID A, ZHAN M, JOHNSON KP, MARTIN R: Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with Th2-biased phenotype. J. Neuroimmunol. (2003) 140:163-171.
19. DUDA PW, KRIEGER JI, SCHMIED MC, BALENTINE C, HAFLER DA: Human and murine CD4 T cell reactivity to a complex antigen: Recognition of the synthetic random polypeptide glatiramer acetate. J. Immunol. (2000) 165: 7300-7307.
20. BRENNER T, ARNON R, SELA A et al.: Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®. J. Neuroimmunol. (2001) 115:152-160.
21. RIEKS M, HOFFMANN V, AKTAS O et al.: Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate. Eur. Neurol. (2003) 50:200-206.
22. CHEN M, CONWAY K, JOHNSON KP, MARTIN R, DHIB-JALBUT S: Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J. Neurological. Sci. (2002) 201:71-77.
23. AHARONI R, TEITELBAUM D, LEITNER O, MESHORER A, SELA AM, ARNON R: Specific Th2 cells accumulate in the nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. USA (2000) 97:11472-11477.
24. BIERNACKI K, PRAT A, BLAIN M, ANTEL JP: Regulation of Th1 and Th2 lymphocyte migration by human adult brain endothelial cells. J. Neuropathol. Exp. Neurol. (2001) 60:1127-1136.
25. AHARONI R, KAYHAN B, EILAM R, ARNON R: Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Natl. Acad. Sci. USA (2003) 100:14157-14162.
26. CHEN M, VALENZUELA M, DHIB-JALBUT S: Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J. Neurol. Sci. (2003) 215:37-44.
27. YONG VW: Differential mechanisms of action of interferon-β and glatiramer acetate in MS. Neurology (2002) 59:802-808.
28. MOALEM G, LEIBOWITZ-AMIT R, YOLES E, MOR F, COHEN IR, SCHWARTZ M: Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. (1999) 5:49-55.
29. KIPNIS J, YOLES E, PORAT Z et al.: T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: Possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. USA (2000) 97:7446-7451.
30. SCHORI H, KIPNIS J, YOLES E et al.: Vaccination for protection of retinal ganglion cells against cell death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma. Proc. Natl. Acad. Sci. USA (2001) 98:3398-3403.
31. GILGUN-SHERKI Y, PANET H, HOLDENGREBER V, MOSBERG-GALILI R, OFFEN D: Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci. Res. (2003) 47:201-207.
32. ANGELOV DN, WAIBEL S, GUNTINAS-LICHIUS O et al.: Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. (2003) 100:4790-4795.
33. KAYHAN B, AHARONI R, ARNON R: Glatiramer acetate (Copaxone®) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis. Immunol. Lett. (2003) 88:185-192.
34. PARKINSON JF, MITROVIC B, MERRILL JE: The role of nitric oxide in multiple sclerosis. J. Mol. Med. (1997) 75:174-186.
35. THOENEN H: Neurotrophins and neuronal plasticity. Science (1995) 270:593-598.
36. ZIEMSSEN T, KUMPFEL T, KLINKERT WEF, NEUHAUS O, HOHLFELD R: Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: Implications for multiple sclerosis therapy. Brain (2002) 125:2381-2391.
37. STADELMANN C, KERSCHENSTEINER M, MISGELD T, BRUCK W, HOHLFELD R, LASSMANN H: BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain (2002) 125:75-85.
38. CHABOT S, YONG FP, LE DM, METZ LM, MYLES T, YONG VW: Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: A mechanism for therapeutic efficacy in multiple sclerosis. Mult. Scler. (2002) 8:299-306.
39. TEITELBAUM D, AHARONI R, SELA M, ARNON R: Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc. Natl. Acad. Sci. (1991) 88:9528-9532.
40. URE DR, ROGRIGUEZ M: Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J. (2002) 16:1260-1262.
41. FARINA C, VARGAS V, HEYDARI N, KUMPFEL T, MEINL E, HOHFELD R: Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J. Neuroimmunol. (2002) 123:188-192.
42. TEITELBAUM D, BRENNER T, ABRAMSKY O, AHARONI R, SELA M, ARNON R: Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult. Scler. (2003) 9:592-599.
43. SALAMA HH, HONG J, ZANG YC, EL-MONGUI A, ZHANG J: Blocking effects of serum reactive antibodies induced by glatiramer acetate in multiple sclerosis. Brain (2003) 126:2638-2647.
44. WOLINSKY JS, TOYKA KV, KAPPOS L, GROSSBERG SE: Interferon-beta antibodies: Implications for the treatment of MS. Lancet Neurol. (2003) 2:528.
45. BORNSTEIN MB, MILLER A, SLAGLE S et al.: A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New Engl. J. Med. (1987) 317:408-414.
46. JOHNSON KP, BROOKS BR, COHEN JA et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology (1995) 45:1268-1276.
47. JOHNSON KP, BROOKS BR, COHEN JA et al.: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology (1998) 50:701-708.
48. JOHNSON KP, BROOKS BR, FORD CC et al.: Glatiramer acetate (Copaxone): Comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult. Scler. (2003) 9:585-591.
49. JOHNSON KP, BROOKS BR, FORD CC et al.: Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult. Scler. (2000) 6:255-266.
50. JOHNSON KP, BROOKS BB, FORD CC et al.: Results of the long-term (8-year) prospective open-label trial of glatiramer acetate for relapsing multiple sclerosis. Presented at the 54th Annual Meeting of the American Academy of Neurology, Denver, USA (2002).
51. WEINSHENKER BG: The natural history of multiple sclerosis. Mult. Scler. (1995) 13:119-144.
52. FORD C, JOHNSON K, BROOKS B et al.: Sustained efficacy and tolerability of glatiramer acetate in relapsing-remitting multiple sclerosis patients for over 10 years. Proceedings of the 19th Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Milan, Italy (2003) Poster 485.
53. BONESCHI FM, ROVARIS M, JOHNSON KP et al.: Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: Meta-analysis of three double-blind, randomized, placebo-controlled trials. Mult. Scler. (2003) 9:349-355.
54. COMI G, FILIPPI M, WOLINSKY JS, and the EUROPEAN/CANADIAN GLATIRAMER ACETATE STUDY GROUP: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann. Neurol. (2001) 49:290-297.
55. WOLINSKY JS, JOHNSON KP, COMI G et al.: The effects of glatiramer acetate on sustained accumulated disability in relapsing multiple sclerosis are evident within one year: Meta-analysis results of three double blind, placebo-controlled trials. Proceedings of the 19th Annual Meeting of the European Committee for Treatment and Research in Mult. Scler. (ECTRIMS), Milan, Italy (2003) Poster 487.
56. ROVARIS M, COMI G, ROCCA MA, WOLINSKY JS, FILIPPI M, and the EUROPEAN/CANADIAN GLATIRAMER ACETATE STUDY GROUP: Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and its implications. Brain (2001) 124:1803-1812.
57. FILIPPI M, ROVARIS M, ROCCA MA et al.: Glatiramer acetate reduces the proportion of new MS lesions evolving into 'black holes'. Neurology (2001) 57:731-733.
58. KHAN O, CHING W, CAON C et al.: Combining immunomodulation and neuroprotection: Cerebral axonal recovery in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate. Proceedings of the 19th Annual Meeting of the European Committee for Treatment and Research in Mult. Scler. (ECTRIMS), Milan, Italy (2003) Poster 268.
59. MANCARDI GL, SARDANELLI F, PARODI RC et al.: Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology (1998) 50:1127-1133.
60. GE Y, GROSSMAN RI, UDUPA JK et al.: Glatiramer acetate (Copaxone) treatment in relapsing-remitting quantitative MRI assessment. Neurology (2000) 54:813-817.
61. WOLINSKY JS, NARAYANA PA, JOHNSON KP, and the COPOLYMER 1 MULTIPLE SCLEROSIS STUDY GROUP: Unites States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult. Scler. (2001) 7:33-41.
62. WOLINSKY JS, COMI G, FILIPPI M et al.: Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology (2002) 59:1284-1286.
63. CARRA A, ONAHA P, SINAY V et al.: A retrospective observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur. J. Neurol. (2003) 10:671-676.
64. KHAN OA, TSELIS AC, KAMHOLZ JA, GARBERN JY. LEWIS RA, LISAK RP: A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex), IFNβ-1b (Betaseron), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis. Eur. J. Neurol. (2001) 8:141-148.
65. KHAN OA, TSELIS AC, KAMHOLZ JA, GARBERN JY, LEWIS RA, LISAK RP: A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex), IFNβ-1b (Betaseron), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: Results after 18 months of therapy. Mult. Scler. (2001) 7:349-353.
66. FLECHTER S, VARDI J, POLLAK L, RABEL JM: Comparison of glatiramer acetate (Copaxone®) and interferon β-1b (Betaferon®) in multiple sclerosis patients: An open-label 2-year follow-up. J. Neurol. Sci. (2002) 197:51-55.
67. FLECHTER S, KOTT E, STEINER-BIRMANNS B, NISIPEANU P, KORCZYN AD: Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: Open multicenter study of alternate-day administration. Clin. Neuropharmacol. (2002) 25:11-15.
68. HAAS J: Onset of clinical benefit of glatiramer (Copaxone) acetate in 255 patients with relapsing-remitting multiple sclerosis. Proceedings of the 55th Annual Meeting of the American Academy of Neurology, Honolulu, USA (2003) P06.105.
69. BENSON K, HARTZ AJ: A comparison of observational studies in randomized, controlled studies. N. Engl. J. Med. (2000) 342:1878-1886.
70. KHAN O, CAON C, ZVARTAU-HIND M, DIN MU, LISAK RP: Clinical course before and after change of immunomodulating therapy in relapsing remitting MS. Proceedings of the 53rd Annual Meeting of the American Academy of Neurology, Philadelphia, USA (2001) PO5.104.
71. CAON C, CHING W, DIN M, ZVARTAU-HIND M, LISAK R, KHAN O: Extended follow-up and clinical course after change of immunomodulatory therapy in relapsing-remitting MS. Proceedings of the 13th Annual Meeting of the European Neurological Society, Istanbul, Turkey (2003).
72. ZWIBEL H, for the COPAXONE TREATMENT IND STUDY GROUP: Benefit of Copaxone demonstrated in patients with relapsing-remitting multiple sclerosis (RRMS) previously treated with interferon. Proceedings of the 11th Annual Meeting of the European Neurological Society. Paris, France (2001) Poster 521.
73. DHIB-JALBUT S: Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology (2002) 58(Suppl. 4):S3-S9.
74. SIMPSON D, NOBAE S, PERRY C: Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs (2002) 16:825-850.
75. MILO R, PANITCH H: Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J. Neuroimmunol. (1995) 61:185-193.
76. LUBLIN F, BAIER M, CUTTER G et al.: Results of the extension of the trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate. Neurology (2002) 58(S3):A85.
77. DHIB-JALBUT S, CHEN M, HENSCHEL K, FORD D, COSTELLO K, PANITCH H: Effect of combined IFNβ-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult. Scler. (2002) 8:485-491.
78. AHARONI R, MESHORER A, SELA M, ARNON R: Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system. J. Neuroimmunol. (2002) 126:58-68.
79. MARON R, SLAVIN AJ, HOFFMANN E, KOMAGATA Y, WEINER HL: Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: Cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines. Int. Immunol. (2002) 14:131-138.
80. WOLINSKY JS, PROMISE STUDY GROUP: The diagnosis of primary progressive multiple sclerosis. J. Neurol. Sci. (2003) 206:145-152.
81. FUSCO C, ANDREONE V, COPPOLA G et al.: HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology (2001) 57:1976-1979.
82. FARINA C, WAGENPFEIL S, HOHLFELD R: Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis: A pilot study. J. Neurol. (2002) 249:1587-1592.
83. KORNEK B, BERNERT G, BALASSY C, GELDNER J, PRAYER D, FEUCHT M: Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics (2003) 34:120-126.
84. MANCARDI GL, MURIALDO A, DRAGO F et al.: Localized lipoatrophy after prolonged treatment with copolymer 1. J. Neurol. (2000) 247:220-221.
85. HWANG L, ORENGO I: Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis. Cutis (2001) 68:287-288.
86. COYLE PK, JOHNSON KP, PARDO L, STARK Y: Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Proceedings of the 19th Annual Meeting of the European Committee for Treatment and Research in Mult. Scler. (ECTRIMS), Milan, Italy (2003) Poster 268.
87. ZIEMMSEN T, NEUHAUS O, HOHLFELD R: Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf. (2001) 24(13):979-990.